CN103393639A - Medicinal composition for treating lung cancer and preparation method thereof - Google Patents
Medicinal composition for treating lung cancer and preparation method thereof Download PDFInfo
- Publication number
- CN103393639A CN103393639A CN2013102800204A CN201310280020A CN103393639A CN 103393639 A CN103393639 A CN 103393639A CN 2013102800204 A CN2013102800204 A CN 2013102800204A CN 201310280020 A CN201310280020 A CN 201310280020A CN 103393639 A CN103393639 A CN 103393639A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- curcumin
- dihydroarteannuin
- hepatoma therapy
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a medicinal composition for treating lung cancer and a preparation method thereof. The composition is prepared from the following drugs in parts by weight: 5-50 parts of curcumin, 5-30 parts of dihydroartemisinin, and is prepared from conventional auxiliary materials according to a conventional process to form a conventional preparation. Curcumin and dihydroartemisinin are combined to take a synergic effect and have a remarkable treatment effect over single application, and can be used for well inhibiting cell growth of lung cancer, so that pains of patients can be greatly relieved.
Description
Technical field
The present invention relates to the Medicinal invention field, be specifically related to pharmaceutical composition of a kind of Hepatoma therapy and preparation method thereof.
Background technology
Cancer is common frdquently encountered disease, and the people's life and healthy in serious harm, and the position difference due to pathogenesis of cancer, can have various cancer, as hepatocarcinoma, gastric cancer, osteocarcinoma, skin carcinoma, intestinal cancer etc.Hepatocarcinoma (liver cancer) is the third-largest common cancer that mortality rate is only second to gastric cancer, esophageal carcinoma, initial stage symptom not obvious, late period main manifestations be liver pain, weak, become thin, the symptoms such as jaundice, ascites.Generally take clinically operation, chemicotherapy and the Chinese Medicine and Clavicular therapy of doctor trained in Western medicine, but patients with terminal is lower because of cancerous cell diffusion cure rate, therefore will accomplishes early discovery, early diagnosis, the early treatment of hepatocarcinoma.Hepatocarcinoma belongs to the categories such as " the liver rump ", " mass at the hypochondrium ", " expansion " more in tcm clinical practice.Motherland's medical science thinks that primary hepatocarcinoma is that the liver spleen is become estranged because the evil delay of the damp and hot poison of impression is detained, due to diet internal injury, seven emotions pent-up etc., and QI and blood expectorant poison stasis venation is with the passing of time gradually built up in bulk and is stopped at flank and forms.The Coryza Treated by Syndrome Differentiation of the traditional Chinese medical science to primary hepatocarcinoma. mainly with invigorating the spleen and benefiting QI, be main, cooperationization addiction softening the hard mass, heat-clearing and toxic substances removing, embody hepatocarcinoma take the pathogenesis of void as basis, deficiency in origin and excess in superficiality.First when consolidating, then regulated the flow of vital energy according to clinical symptoms, the method for blood stasis dispelling and heat-clearing and toxic substances removing.The mechanism of the Chinese medicinal formulae Hepatoma therapy that uses at present is that spleen invigorating regulates the flow of vital energy, and removing blood stasis is anticancer." golden plaque outline " cloud: " seeing the disease of liver, knowing the liver disease will be transmitted into the spleen ".Advanced liver cancer, present liver mistake bar more and reach, dysfunction of the spleen in transportation, and two is dirty with sick.
In sum, hepatocarcinoma is a global difficult problem, therefore how Hepatoma therapy, the misery that reduces patient is present urgent problem, " hour hands traditional Chinese medical science traditional Chinese medicines " the 20th the 2nd phase of volume in 2009 discloses the effect that curcumin has Hepatoma therapy, and " Chinese medical forward position " o. 11th in 2012 discloses dihydroarteannuin and had the human hepatoma cell of inhibition strain HepG2 growth.But regrettably the effect of these two kinds of independent Hepatoma therapies of medicine is not very desirable, the applicant is through studying for a long period of time, through experimental results demonstrate, curcumin and dihydroarteannuin are used in combination, can play synergism, therapeutic effect obviously is better than independent use, has well suppressed the growth of hepatoma carcinoma cell, has solved greatly patient's misery.
Summary of the invention
The pharmaceutical composition that the purpose of this invention is to provide a kind of Hepatoma therapy.
Another object of the present invention is to provide a kind of preparation method of pharmaceutical composition of Hepatoma therapy.
The present invention also provides the application of compositions in Hepatoma therapy.
The objective of the invention is to be achieved through the following technical solutions:
Pharmaceutical composition of the present invention is:
Curcumin 5-50 part, dihydroarteannuin 5-30 part.
Pharmaceutical composition of the present invention is preferably:
Curcumin 10-45 part, dihydroarteannuin 8-25 part.
Pharmaceutical composition of the present invention is preferably:
Curcumin 15-40 part, dihydroarteannuin 10-23 part.
Pharmaceutical composition of the present invention is preferably:
Curcumin 20-35 part, dihydroarteannuin 12-20 part.
Pharmaceutical composition of the present invention is preferably:
25 parts of curcumins, 15 parts of dihydroarteannuins.
Pharmaceutical composition of the present invention is preferably:
0 part of bisdemethoxycurcumin, 18 parts of dihydroarteannuins.
Pharmaceutical composition preparation method of the present invention is following steps:
Take curcumin, the dihydroarteannuin mix homogeneously of weight portion, technique adds conventional adjuvant and is processed into regular dosage form routinely.
Described pharmaceutically acceptable carrier or diluent refer to the pharmaceutical carrier of pharmaceutical field routine, are selected from one or more in filler, binding agent, disintegrating agent, lubricant, surfactant or correctives, diluent, wherein:
Described filler is selected from starch, sucrose, lactose, mannitol, sorbitol, xylitol, microcrystalline Cellulose or glucose etc.
Described binding agent is selected from cellulose derivative, alginate, gelatin or polyvinylpyrrolidone etc.
Described disintegrating agent is selected from microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose or cross-linking sodium carboxymethyl cellulose.
Described lubricant is selected from stearic acid, Polyethylene Glycol, calcium carbonate, sodium bicarbonate, micropowder silica gel, Pulvis Talci or magnesium stearate.
Described surfactant is selected from dodecylbenzene sodium sulfonate, stearic acid, Pluronic F68, the fatty acid Pyrusussuriensis is smooth or Polysorbate (tween) etc.
Described correctives is selected from aspartame, Sucralose or saccharin sodium.
Described diluent is Chinese liquor, water, glycerol etc.
The present invention also provides the application of said composition in Hepatoma therapy.
Pharmaceutical composition provided by the invention has the following advantages:
1, with in prior art compare:
Of the prior art by curcumin and dihydroarteannuin medicine separately for the treatment of hepatocarcinoma, effect is also not obvious, the applicant is through studying for a long period of time, through experimental results demonstrate, curcumin and dihydroarteannuin are used in combination, can play synergism, therapeutic effect obviously is better than independent use, well suppress the growth of hepatoma carcinoma cell, solved greatly patient's misery.
2, through clinical practice, can obviously extend survival, improve patient's life quality.
3, can obviously improve patient's clinical symptoms, coordinate interventional therapy and the Moving-strip radiotherapy technology of doctor trained in Western medicine to have significant synergism and attenuation.
The specific embodiment
Following examples are used for the present invention is described, but are not used for limiting the scope of the invention.
Embodiment 1: the capsule of pharmaceutical composition of the present invention
Prescription: curcumin 5g, dihydroarteannuin 5g.
Technique: curcumin, the dihydroarteannuin of getting weight portion mix, and add the starch of 0.5 times of amount, mix, and incapsulate, and obtain capsule of the present invention.
Embodiment 2: the granule of pharmaceutical composition of the present invention
Prescription: curcumin 50g, dihydroarteannuin 30g.
Technique: curcumin, the dihydroarteannuin of getting weight portion mix, and add the starch of 1 times of amount, mix, and granulate, and obtain granule of the present invention.
Embodiment 3: the tablet of pharmaceutical composition of the present invention
Prescription: curcumin 25g, dihydroarteannuin 15g
Technique: curcumin, the dihydroarteannuin of getting weight portion mix, and add the starch of 1.5 times, mix, and tabletting, obtain tablet of the present invention.
Embodiment 4: the injection of pharmaceutical composition of the present invention
Prescription: bisdemethoxycurcumin 0g, dihydroarteannuin 18g.
Technique: curcumin, the dihydroarteannuin of getting weight portion mix, and add 1000 liters of waters for injection, and with the filtering with microporous membrane of 0.45 μ m, stir and made mix homogeneously in 30 minutes, embedding, sterilizing, obtain injection of the present invention.
Embodiment 5: the oral liquid of pharmaceutical composition of the present invention
Prescription: curcumin 15g, dihydroarteannuin 10g.
Technique: curcumin, the dihydroarteannuin of getting weight portion mix, and add 500 premium on currency, mix, and filter, and sterilizing, bottling, obtain oral liquid of the present invention.
Embodiment 6: the preventive and therapeutic effect of pharmaceutical composition of the present invention to liver cancer mouse model
(1) preparation of transplanted hepatoma mouse model
72 of the healthy kunming mices of SPF level, half and half, 6 age in week of male and female, body weight 16g-18g.Get exponential phase H22 (S type) hepatoma carcinoma cell of In vitro culture, adjusting oncocyte concentration is 1X10/mL.Under aseptic condition, oncocyte is inoculated in to the right armpit of mice subcutaneous, inoculum concentration is 0.2m1/ only (cell number is 2X106/).Whole seeded process must be carried out with sterile working in aseptic cover, in lh, complete inoculation.When subcutaneous transplantation tumor volume reaches the 60mm left and right (about lOd), the model manufacturing success.
(2) grouping and administration
By tumor volume and mice with tumor body weight homeostatic principle, be divided into following 6 groups, 12 every group.
Model control group: 1 times/day of the normal saline of gavage equivalent, administration is 40 altogether;
Pharmaceutical composition low dose group of the present invention: gavage gives the embodiment oral liquid of 5 preparations, and dosage is 20mg/kg, and 1 times/day, administration is 40 altogether;
Pharmaceutical composition high dose group of the present invention: gavage gives the embodiment drug composition oral liquid of 5 preparations, and dosage is 50mg/kg, and 1 times/day, administration is 40 altogether;
Ring phosphorus phthalein amine group: tail vein injection 25mg/kg ring phosphorus phthalein amine, the next day administration 1 time, amount to 10 times.
Curcumin group: 50mg/kg, 1 times/day, administration is 40 altogether;
Dihydroarteannuin group: 50mg/kg, 1 times/day, administration is 40 altogether;
After last administration 48h, mice is put to death in dislocation, and excision transplanted tumor, take the tumor weight.
Heavy suppression ratio (%) IR bis-(the 1 one administration group tumor weight-average value/model control group tumor weight-average value) X100% of tumor.
By what tumor weighed, relatively embody medicine to the liver cancer mouse model preventive and therapeutic effect.Data with mean standard deviation ((
) expression, adopt SPSS15.0 software to carry out variance analysis.
(3) results and analysis
Result of the test shows (referring to table 1): with model control group, compare, each treatment group all has utmost point significant difference (P<0.01) to the preventive and therapeutic effect of rat liver cancer model, and this explanation pharmaceutical composition of the present invention has extremely significant curative effect aspect Hepatoma therapy.With the curcumin group, compare, preventive and therapeutic effect all has utmost point significant difference (P<0.01), and this explanation pharmaceutical composition of the present invention obviously is better than the curcumin group aspect Hepatoma therapy, have synergistic function; With the dihydroarteannuin group, compare, preventive and therapeutic effect all has utmost point significant difference (P<0.01), and this explanation pharmaceutical composition of the present invention obviously is better than the dihydroarteannuin group aspect Hepatoma therapy, have synergistic function; In addition, pharmaceutical composition of the present invention is compared aspect tumour inhibiting rate and be there is no significant difference with chemotherapy ring phosphorus phthalein amine group, and 2 of the dead mouses of the rear chemotherapy group of administration end, the curative effect of this explanation pharmaceutical composition of the present invention is suitable with chemotherapeutics, and when obtaining remarkable drug effect, have the advantage that toxic and side effects is low, obtained unforeseeable technique effect.This test repeats twice continuously, and result is substantially similar.
The preventive and therapeutic effect of table 1 pharmaceutical composition of the present invention to liver cancer mouse model
Embodiment 7: clinical observation on the therapeutic effect
Pharmaceutical composition of the present invention is for the primary hepatocarcinoma post-operative treatment, and result shows, can obviously reduce cancer return rate, the rate of transform; For getting involved postoperative adjuvant therapy, has very strong potentiation; Can obviously extend the mid and late liver cancer patient life cycle, improve its quality of life.
The present invention to the primary hepatocarcinoma interventional procedure after, the postoperative clinical patients tcm syndrome of radio frequency and the improvement situation of quality of life be studied and analyze:
The object of observation is: December Shuguang Hospital oncology outpatient service 1 years January in 2005 and inpatient amount to 300 examples, male's 259 examples wherein, women's 41 examples; Age is between 32 1 65 years old.Mean age is (51 scholar 10.2) year.
Be divided at random matched group 150 examples, treatment group 150 examples; Matched group gives simple interventional therapy, and treatment group gets involved associating medicine composite for curing of the present invention.
Observation index comprises: patient clinical tcm syndrome curative effect, quality of life, tumor body short term effect, life cycle; Safety is observed, cellular immune function.
Symptom before patient treatment take xerostomia, hypochondriac pain, soreness of the waist and knees, ascites, weak, indigestion and loss of appetite, abdominal distention, be in a very depressed state, dizzy, dysphoria with feverish sensation in the chest palms and soles, night sweat, tinnitus etc. are as main, after medicine composite for curing of the present invention, the frequency distribution of multinomial symptom is front obviously to descend, and has statistical significance (P<0.05).
Table 2 is that before and after treatment, frequency distribution situation n=300 example (%) appears in clinical symptoms.
| Clinical symptoms | Before treatment | After treatment | The P value |
| Hypochondriac pain | 246(82.0%) | 163(54.3%) | <0.001 |
| Be in a very depressed state | 214(71.3%) | 76(25.3%) | <0.001 |
| Dizzy | 118(39.3%) | 41(13.7%) | <0.001 |
| Soreness of the waist and knees | 236(78.7%) | 50(16.7%) | <0.001 |
| Tinnitus | 107(35.7%) | 57(19.0%) | <0.001 |
| Heating | 96(32.0%) | 90(30.0%) | >0.05 |
| Dysphoria with feverish sensation in the chest palms and soles | 121(40.3%) | 32(10.7%) | <0.001 |
| Night sweat | 143(47.7%) | 35(11.7%) | <0.001 |
| Xerostomia | 211(70.3%) | 67(22.3%) | <0.001 |
| Constipation | 69(23.0%) | 40(13.3%) | <0.001 |
| Weak | 273(91.0%) | 45(15.0%) | <0.001 |
| Indigestion and loss of appetite | 248(82.7%) | 120(40.0%) | <0.001 |
| Abdominal distention | 172(57.3%) | 114(38%) | <0.001 |
| Mass in the abdomen | 103(34.3%) | 103(34.3%) | >0.05 |
| Dim complexion | 94(31.3%) | 89(29.7%) | >0.05 |
| Ascites | 195(65.0%) | 53(17.7%) | <0.001 |
| Edema of lower limbs | 14(4.7%) | 10(3.3%) | >0.05 |
| Jaundice | 32(10.7%) | 34(11.3%) | >0.05 |
| Limbs are tired heavy | 31(10.3%) | 30(10.0%) | >0.05 |
| Bitter taste | 37(12.3%) | 12(4.0%) | <0.001 |
| Dry stool | 24(8.0%) | 10(3.3%) | >0.05 |
| Ripple is red | 21(7.0%) | 20(6.7%) | >0.05 |
| Fear of cold | 3(1.0%) | 0(0) | >0.05 |
| Nocturia frequently | 4(1.3%) | 0(0) | >0.05 |
In the routine patient of viewing duration 300, treatment group 144 examples obtain to follow up a case by regular visits to, and 6 examples are lost to follow-up, and matched group 142 examples obtain to follow up a case by regular visits to, and 8 examples are lost to follow-up, total rate 4.67% lost to follow-up (14/300 example).
Result shows:
The clinical efficacy of tcm syndrome: 144 routine patients after liver cancer treatment, produce effects 25 examples, effective 98 examples, total effective rate is 82.00%.
Quality of life KPS scoring: before patient treatment, quality of life KPS scoring is (76.53 scholar 4.37) minute, after treatment, be (86.12 scholar 7.41) minute, before after treatment, treating, have clear improvement, difference have statistical significance ((P<0.01).
Tumor body short term effect: treatment group can be estimated case 144 examples after treatment, without the CR case, and PR25 example, SD98 example, PD29 example; Matched group can be estimated case 142 examples, without the CR case, and PR15 example, SD75 example, PD52 example.Treatment group disease control rate (CR+PR+SD is 85.42%) is higher than matched group (63.38%), and two groups of comparing differences have statistical significance (definite probabilistic method Fisher'sExactTest, P=0.035).
Table 3 tumor body short term effect
Life cycle: 0.5 year survival rate 82.00% (123/144 example) for the treatment of group, 1 year survival rate 67.36% (70/144 example), 1.5 years survival rates 29.17% (42/144 example), 2 years survival rates 13.89% (20/144 example); Matched group is followed successively by 63.38% (90/142 example), 35.21% (50/142 example), 14.79% (21/142 example) and 4.93% (7/142 example).
Treatment group 1 year, 1.5 years, survival rate was better than matched group (P<0.05) in 2 years, 0.5 year survival rates of two groups comparing difference not statistically significant.
Table 4 primary hepatocarcinoma is got involved in postoperative patient 2 years survival rate relatively
Safety evaluatio: in therapeutic process, two groups all have small number of patients the untoward reaction such as heating, nausea and vomiting, hepatalgia to occur, but all slight, consideration is relevant with intervention or radio-frequency (RF) therapy, after anti symptom treatment, can alleviate, and has no other serious adverse reactions.
Cellular immunization: two groups of patient T lymphopoiesis SI values change after 1 course for the treatment of and have 286 routine patients and carry out this detection, treatment group 144 examples, matched group 142 examples.Before and after the treatment group treatment, SI changes statistical significance (P<0.05),
Lower than (24.39/28.17) before treating, namely after the treatment, treatment group patient SI descends in conjunction with the average several after the sample data treatment, and remainder is according to having no significant change.SI comparing difference not statistically significant after two groups of treatments (P > 0.05).
After table 5 liang group treatment, T lymphopoiesis SI changes
After two groups of patient treatments, onthe surface of monocytes MHCI/II molecule and B7 developed by molecule change (as shown in table 6)
Before and after treatment, have 282 routine patients and carry out this detection, treatment group 144 examples, matched group 142 examples.Mononuclear cell table before and after treatment group treatment and the expression difference of HLA2DR has statistical significance ((P<0.01), mean rank order after treating in conjunction with sample data is higher than (27/11) before treating, namely after the treatment, treatment group patient onthe surface of monocytes HLA2DR expression is improved, and remainder is according to having no significant change.The variation not statistically significant of onthe surface of monocytes MHCI/II molecule and B7 developed by molecule after two groups of treatments ((P > 0.05).
After table 6 liang group treatment, onthe surface of monocytes MHCI/II molecule and B7 developed by molecule change (fluorescence intensity)
Experimental result of the present invention also shows; pharmaceutical composition of the present invention has the effect of cell death inducing: by setting up diethylnitrosamine (DEN), induce Rat Model Carrying Hepatocellular Carcinoma; respectively at luring, adopt Immunohistochemical Staining to detect pharmaceutical composition the kidney invigorating treatment front and back rat hepatocytes PCNA of the present invention at the 12nd weekend of cancer and the 18th weekend; P53 albumen; result demonstration, P53 positive cell are found in the front hepatocellular hyperplastic nodule of cancer; Luring the 12nd weekend of cancer and the 18th weekend all can obviously suppress P53
Positive expression (P<0.05), significantly reduce PCNA-LI and express that ((P<0.01) shows this
The invention medicine is before the P53 gene mutation can betide liver cancer in the Rat Model Carrying Hepatocellular Carcinoma that DEN induces
Pathological changes, the start-up course of participation hepatocarcinoma, can effectively intervene the sudden change of hepatocellular proliferation activity and P5, thereby delay the formation of hepatocarcinoma.
medicine of the present invention has antioxidation, remove the effect of oxygen-derived free radicals, research shows syndrome of yin deficiency of liver and kidney and blood fat, energy metabolism, the relation of radical reaction is comparatively close, hepatic and renal YIN deficiency patient shows as energy metabolism and strengthens, the increase of isolemon dehydrogenase activity and the enhancing of radical reaction appear, thereby the pathological reaction of " deficiency of YIN is given birth to interior-heat " appears, C-AMP in the deficiency of the kidney yin patient blood, ZZ++, Cu++ content is apparently higher than the normal person, result of study shows: ring phosphorus phthalein amine is inhibited to antioxidant system, medicine of the present invention is the inhibitory action of energy antagonism ring phosphorus phthalein amine all, point out it to improve the SOD vigor, the content that reduces MDA may be the dominant mechanism place of its antimutagenic effect.
Medicine low dosage of the present invention can suppress new liver cancer tissue tumor-blood-vessel growth and correlation factor VFGF thereof, bFGF expresses, p<0.05, suppress the weight and volume of people's hepatocarcinoma transplanting nude mice postoperative recurrence tumor and compare P=0.06 with matched group, high dose improves mice weight, with low dose group, compare p<0.05, point out suitable dosage to reach can either to improve mice weight (life quality) and can effectively suppress weight and the volume of new tumor again.
Medicine of the present invention has carried out experiment and the clinical research of the prevention of recurrence of primary hepatocarcinoma patients after surgery, adopts dihydroarteannuin, curcumin to be contrast, observes the impact of liver cancer patient Ka Shi scoring and main clinic symptoms; Result shows, medicine of the present invention is to the common disease of described pattern of syndrome hepatocarcinoma: indigestion and loss of appetite, spiritlessness and weakness, 3 courses for the treatment of of soreness of waist and knee integration and 6 courses for the treatment of are compared and significant difference are all arranged (P<0.05); 3 of the side of body rib dull pain zero difference course for the treatment of, 6 the course for the treatment of integration significant difference (P<0.05) appears; Two groups of emotion aspect integrations are zero difference (P > 0.05) all the time; Karnofsky scoring improvement situation improves compares obvious raising with matched group with the person of stablizing, after 3 courses for the treatment of, compare and have statistical significance, difference (P<0.05); Liver function index GGT level obviously descends, P<0.05; With matched group, compare, medicine of the present invention can obviously improve the NK cell quantity.
This area thinks, the target of the capable surgical radical treatment of liver cancer patient or interventional therapy is not merely in order to dwindle the tumor piece and to extend the survival of patients time, improving and safeguard patient's life quality no less important.Experiment and clinical research result show: medicine of the present invention is better than using separately dihydroarteannuin or curcumin sodium to the improvement of liver cancer patient muscle power situation, main clinic symptoms, show that medicine of the present invention can improve the clinical symptoms of liver cancer patient effectively, improve life quality.
Although, above used general explanation, the specific embodiment and test, the present invention is described in detail, on basis of the present invention, can make some modifications or improvements it, and this will be apparent to those skilled in the art.Therefore, these modifications or improvements, all belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (10)
1. the pharmaceutical composition of a Hepatoma therapy, is characterized in that the ingredients by following weight portion: curcumin 5-50 part, dihydroarteannuin 5-30 part.
2. the pharmaceutical composition of a kind of Hepatoma therapy according to claim 1, is characterized in that the ingredients by following weight portion: curcumin 10-45 part, dihydroarteannuin 8-25 part.
3. the pharmaceutical composition of a kind of Hepatoma therapy according to claim 1, is characterized in that the ingredients by following weight portion: curcumin 15-40 part, dihydroarteannuin 10-23 part.
4. the pharmaceutical composition of a kind of Hepatoma therapy according to claim 1, is characterized in that the ingredients by following weight portion: curcumin 20-35 part, dihydroarteannuin 12-20 part.
5. the pharmaceutical composition of a kind of Hepatoma therapy according to claim 1, is characterized in that the ingredients by following weight portion: 25 parts of curcumins, 15 parts of dihydroarteannuins.
6. the pharmaceutical composition of a kind of Hepatoma therapy according to claim 1, is characterized in that the ingredients by following weight portion: 0 part of bisdemethoxycurcumin, 18 parts of dihydroarteannuins.
7. the pharmaceutical composition of a kind of Hepatoma therapy according to claim 1 is characterized in that its preparation method is following steps: take curcumin, the dihydroarteannuin mix homogeneously of weight portion, technique adds conventional adjuvant and is processed into regular dosage form routinely.
8. the preparation method of the pharmaceutical composition of a kind of Hepatoma therapy according to claim 7 is characterized in that: described adjuvant is that pharmaceutically acceptable carrier or diluent form.
9. the pharmaceutical composition of a kind of Hepatoma therapy according to claim 7, is characterized in that described dosage form is injection, tablet, capsule, granule, soft capsule, oral liquid, drop pill, lyophilized injectable powder, spray, patch.
10. the pharmaceutical composition of the described Hepatoma therapy of according to claim 1-6 any one, is characterized in that the application of said composition in Hepatoma therapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102800204A CN103393639A (en) | 2013-07-04 | 2013-07-04 | Medicinal composition for treating lung cancer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102800204A CN103393639A (en) | 2013-07-04 | 2013-07-04 | Medicinal composition for treating lung cancer and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103393639A true CN103393639A (en) | 2013-11-20 |
Family
ID=49557500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102800204A Pending CN103393639A (en) | 2013-07-04 | 2013-07-04 | Medicinal composition for treating lung cancer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103393639A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105963637A (en) * | 2016-06-15 | 2016-09-28 | 中山大学 | Application of combination of cryptotanshinone and curcumin in preparation of drug for treating tumor |
| WO2018172745A1 (en) * | 2017-03-21 | 2018-09-27 | St George's Hospital Medical School | Combination therapy for treatment of cancer |
-
2013
- 2013-07-04 CN CN2013102800204A patent/CN103393639A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 孙雅洁等: "青蒿素及其衍生物体外抗肿瘤活性研究", 《解放军药学学报》 * |
| 李汉荣: "探究中药成分在抗肝癌研究中的应用", 《中国卫生产业》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105963637A (en) * | 2016-06-15 | 2016-09-28 | 中山大学 | Application of combination of cryptotanshinone and curcumin in preparation of drug for treating tumor |
| CN105963637B (en) * | 2016-06-15 | 2020-01-14 | 中山大学 | Application of cryptotanshinone and curcumin in preparation of tumor treatment medicine |
| WO2018172745A1 (en) * | 2017-03-21 | 2018-09-27 | St George's Hospital Medical School | Combination therapy for treatment of cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101530597B (en) | Medicament for treating adenofibroma of breast and cyclomastopathy | |
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN104491740A (en) | Traditional Chinese medicine composition for treating liver cancer and preparation method of traditional Chinese medicine composition | |
| CN103393639A (en) | Medicinal composition for treating lung cancer and preparation method thereof | |
| CN103908611A (en) | Traditional Chinese medicine preparation for treating colon cancer and preparation method of traditional Chinese medicine preparation | |
| CN102293920B (en) | Medicine composition for treating primary liver cancer and preparation method thereof | |
| CN103610795B (en) | A kind of preparation method of eucommia bark depressor oral formulations | |
| CN103385872B (en) | Pharmaceutical composition of a kind of Hepatoma therapy and preparation method thereof | |
| RU2322999C2 (en) | Method for preventing and treating complications at radiation and/or chemotherapy of cancer of different localization | |
| CN104983764A (en) | Application of Babaodan in preparation of drugs for treating pulmonary fibrosis | |
| CN105853463B (en) | A kind of preparation method and application for the Chinese medicine preparation treated ulcerative carbuncle ulcer, promote muscle growth | |
| CN103479642B (en) | Nano sodium cantharidinate composition and preparation method thereof | |
| CN103142931B (en) | Traditional Chinese medicine composite for treating liver cancer and preparation method thereof | |
| CN107335011B (en) | External traditional Chinese medicine compound preparation for treating cancer pain | |
| CN110339237A (en) | A kind of pharmaceutical composition of auxiliary for treating cancer | |
| CN100409852C (en) | Chinese medicine for enhancing immunologic function | |
| CN105031564B (en) | A kind ofly treat Chinese medicine preparation of acute soft tissue bruise and preparation method thereof | |
| CN104623550B (en) | The Chinese medicine for the treatment of sciatica | |
| CN109999143B (en) | Traditional Chinese medicine for treating benign tumor proliferative diseases | |
| CN103040968B (en) | Anticancer Yanshouling | |
| CN104623534A (en) | Anodyne for advanced liver cancer | |
| CN105521100A (en) | Traditional Chinese medicinal composition for treating leucopenia after chemotherapy | |
| CN103316299B (en) | Chinese medicine composition for treating primary liver cancer | |
| CN105582243A (en) | Traditional Chinese medicine composition for treating solar dermatitis | |
| CN104398704A (en) | Traditional Chinese medicine composition for treating stomach cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20131120 |